Breaking News from Maui Derm 2024: Nemolizumab Improves Lesions, Relieves Itch in AD
Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis. The research was presented by Jonathan I Silverberg, MD, Associate Professor of Dermatology and Director of Clinical […]
HS: The Disease of the Decade
Thanks to new treatments and a full pipeline, hidradenitis suppurativa (HS) is finally getting its due. Raj Chovatiya, MD, PhD, an Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine in Chicago, discusses what these new and coming treatments mean for HS patients and the dermatologists who treat them.
AA Pipeline Watch: Sun Pharma’s Deuruxolitinib Performs Well in New Phase 3 Data
Twice-daily dosing of deuruxolitinib resulted in significant hair regrowth for adults with moderate-to-severe alopecia areata (AA), and these improvements were visible as early as 12 weeks and lasted throughout the 24-week study, according to the Phase 3 THRIVE-AA2 trial. The new results, presented as a late breaker at Maui Derm 2024, are consistent with earlier data on the Janus kinase […]
Can PsA Be Prevented in Psoriasis Patients?
Blocking IL-23 may be the best mechanism of action for trying to prevent new-onset psoriatic arthritis (PsA) in psoriasis patients. Bruce Strober, MD, PhD, a Clinical Professor of Dermatology at Yale University School of Medicine and co-founder of Central Connecticut Dermatology, reviews the data on this novel concept.
Alopecia Areata Update
Jerry Shapiro, MD, Professor and Director of Disorders of the Hair and Scalp at New York University’s Grossman School of Medicine in New York City, discusses how ritlecitinib (Litfulo, Pfizer) and baricitinib (Olumiant, Lilly) are improving the lives of people with alopecia areata.
Revealed: Game-changing Non-surgical Cosmetic Combinations
Synergistic combinations of energy-based devices, neuromodulators, and fillers are taking nonsurgical cosmetic results to the next level. Suneel Chilukuri, MD, Director of Cosmetic Surgery at Refresh Dermatology in Houston, explains how today’s minimally invasive combinations achieve aesthetic results that rival those once only seen with surgery.
Breaking News from Maui Derm 2024: Bimekizumab Shows Maintenance of Response in HS
Bimekizumab demonstrated sustained response in hidradenitis suppurativa (HS), according to a late breaker presented at Maui Derm 2024. Almost all patients who responded after an initial 16 weeks of bimekizumab treatment maintained HiSCR50 (Hidradenitis Suppurativa Clinical Response) and AN count of 0, 1, or 2 clinical response rates through Wk48, the study showed. Bimekizumab, a […]
Done Deal: LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
LEO Pharma now owns TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. The TMB-001 project aims to develop a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis – a skin disease with significant unmet need and no approved prescription therapies available. The TMB-001 project […]